Advances in medical diagnosis, treatment, and care (AMDTC) book series,
Journal Year:
2024,
Volume and Issue:
unknown, P. 205 - 234
Published: Aug. 28, 2024
Bispecific
T-cell
engagers
(BiTEs)
is
a
novel
subclass
of
T-cell-engaging
bispecific
antibodies
(bulbs)
that
are
promising
for
the
treatment
cancer.
BiTEs
direct
cytotoxic
activity
towards
malignant
cells,
resulting
in
targeted
destruction
tumor
cells.
This
chapter
provides
an
overview
current
landscape
BiTE
therapy,
highlighting
its
efficacy
hematologic
malignancies
such
as
B-cell
acute
lymphoblastic
leukemia
(B-ALL)
and
exploring
potential
applications
solid
tumors.
Additionally,
challenges
immunogenicity,
stability,
off-target
effects
were
discussed,
alongside
ongoing
efforts
to
overcome
these
obstacles
through
protein
engineering
combination
therapies.
Future
directions
therapy
include
optimizing
delivery
methods
strategies.
Overall,
represents
approach
cancer
treatment,
with
revolutionize
immunotherapy
improve
patient
outcomes.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(18), P. 9848 - 9848
Published: Sept. 12, 2024
Malignant
melanoma
outcomes
have
drastically
changed
in
recent
years
due
to
the
introduction
of
immune
checkpoint
inhibitors
(ICIs).
However,
many
patients
still
experience
intolerable
side
effects,
therapy
resistance,
and
disease
progression
on
ICI
therapy.
Therefore,
there
remains
a
need
for
novel
therapeutics
that
address
this
gap
treatment
options.
Cell-based
therapies
gained
wide
attention
as
therapeutic
option
could
options
advanced
melanoma.
These
work
by
extracting
certain
cell
types
produced
human
body
such
T-cells,
modifying
them
based
specific
target,
transfusing
back
into
patient.
In
realm
cancer
therapy,
cell-based
utilize
cells
target
tumor
while
sparing
healthy
cells.
Recently,
Food
Drug
Administration
(FDA)
has
approved
usage
lifileucel,
tumor-infiltrating
lymphocyte
(TIL)
This
came
following
results
from
C-144-01
study
(NCT02360579),
which
demonstrated
efficacy
safety
TILs
metastatic
who
otherwise
failed
standard
ICI/targeted
Thus,
trial
well
FDA
approval
proven
viability
utilizing
fill
with
review
aims
provide
comprehensive
overview
major
been
utilized
delineating
most
multi-center
phase
II/
III
clinical
trials
evaluate
Additionally,
we
summary
current
limitations
each
future
direction
how
further
extrapolate
these
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Nov. 20, 2024
Tumor
immune
microenvironment
(TIME)
plays
a
key
role
to
understand
how
tumors
respond
prostate
cancer
(PC)
therapies
and
potential
mechanisms
of
resistance.
Previous
research
has
suggested
that
specific
genomic
aberrations,
such
as
microsatellite
instability
(MSI)
or
CDK12
bi-allelic
loss
can
allow
PC
patients
more
likely
checkpoint
inhibitors
(ICI)
other
therapies.
However,
responses
these
treatments
remain
highly
variable
even
in
selected
patients.
Thus,
it
is
essential
obtain
information
about
tumor
cells
infiltrate
tumors,
on
their
plasticity
interactions,
order
better
the
underlying
biology
development
new
therapeutic
strategies.
This
review
analyzes:
1)
How
interactions
among
cell
populations
infiltrating
stroma
modulate
progression
PC,
2)
standard
treat
(such
androgen
deprivation
therapy,
androgen-directed
hormone
therapy
chemotherapy)
may
influence
dynamic
changes
immunome
3)
What
are
limitations
characterizing
landscape
host´s
response
tumors.
Current Opinion in Urology,
Journal Year:
2023,
Volume and Issue:
33(5), P. 390 - 395
Published: June 30, 2023
Purpose
of
review
Immunotherapy,
a
treatment
modality
currently
synonymous
with
immune
checkpoint
blockade
remains
challenge
for
prostate
cancer.
Despite
multiple
phase
3
trials
using
inhibitors
in
combinatorial
approaches,
there
have
been
no
benefits
to
date
overall
survival
or
radiographic
progression
free
survival.
However,
newer
strategies
prevail
that
are
directed
variety
unique
cell
surface
antigens.
These
include
vaccines,
chimeric
antigen
receptor
(CAR)
T,
bispecific
T
engager
platforms,
and
antibody-drug
conjugates.
Recent
findings
New
antigens
being
targeted
by
various
immunologic
strategies.
pan-carcinoma
as
they
may
be
expressed
on
cancers
but
effective
targets
therapeutic
attack.
Summary
Immunotherapy
alone
combination
agents
such
chemotherapy,
poly-ADP
ribose
polymerase
(PARP)
novel
biologics
met
failure
the
endpoints
(OS)
progresson-free
(rPFS).
these
efforts,
other
efforts
develop
tumor-targeted
should
continued.
Deleted Journal,
Journal Year:
2024,
Volume and Issue:
32(3), P. 200821 - 200821
Published: May 29, 2024
Bispecific
T
cell
engagers
are
a
promising
class
of
therapeutic
proteins
for
cancer
therapy.
Their
potency
and
small
size
often
come
with
systemic
toxicity
short
half-life,
making
intravenous
administration
cumbersome.
These
limitations
can
be
overcome
by
tumor-specific
Advances in medical diagnosis, treatment, and care (AMDTC) book series,
Journal Year:
2024,
Volume and Issue:
unknown, P. 205 - 234
Published: Aug. 28, 2024
Bispecific
T-cell
engagers
(BiTEs)
is
a
novel
subclass
of
T-cell-engaging
bispecific
antibodies
(bulbs)
that
are
promising
for
the
treatment
cancer.
BiTEs
direct
cytotoxic
activity
towards
malignant
cells,
resulting
in
targeted
destruction
tumor
cells.
This
chapter
provides
an
overview
current
landscape
BiTE
therapy,
highlighting
its
efficacy
hematologic
malignancies
such
as
B-cell
acute
lymphoblastic
leukemia
(B-ALL)
and
exploring
potential
applications
solid
tumors.
Additionally,
challenges
immunogenicity,
stability,
off-target
effects
were
discussed,
alongside
ongoing
efforts
to
overcome
these
obstacles
through
protein
engineering
combination
therapies.
Future
directions
therapy
include
optimizing
delivery
methods
strategies.
Overall,
represents
approach
cancer
treatment,
with
revolutionize
immunotherapy
improve
patient
outcomes.
